Richard Woessner

Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.

Richard Woessner, Michael R. Mattern, Christopher K. Mirabelli et al. · PubMed · 1991 · 462 citations

Life Sciences, Cell Biology, Molecular Biology +14

AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

David S. Hong, Razelle Kurzrock, Youngsoo Kim et al. · Science Translational Medicine · 2015 · 440 citations · Full text

Medicine, Cancer Biology, Oncology +8

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Matthew J. Reilley, Patricia McCoon, Carl Cook et al. · Journal for ImmunoTherapy of Cancer · 2018 · 288 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

James F. Blake, Rui Xu, Josef R. Bencsik et al. · Journal of Medicinal Chemistry · 2012 · 188 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones et al. · Blood · 2012 · 172 citations · Full text

Medicine, Oncology, Pharmacology +17